以 CD22 为靶点治疗系统性自身免疫性疾病。
Targeting CD22 as a strategy for treating systemic autoimmune diseases.
出版信息
Ther Clin Risk Manag. 2007 Oct;3(5):953-9.
B-cells play an important role in the diagnosis and to some extent the pathogenesis of many autoimmune diseases. Specific B-cell directed antibodies are now gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and introduction of rituximab in the management of B-cell malignancies as well as rheumatoid arthritis. A second candidate target is CD22, and the first antagonistic antibody to this B-cell marker is epratuzumab, which appears to function, in contrast to CD20 antibodies, more by modulation of B-cells than by their depletion capacity. Originally developed for the treatment of non-Hodgkin lymphoma, epratuzumab has now been reported to be effective, with a very good safety profile, in two prototype autoimmune diseases, systemic lupus erythematosus and primary Sjögren's syndrome. As such, this new investigational antibody may provide distinct therapeutic effects and may be complementary to the known effects and role of CD20 antibodies.
B 细胞在许多自身免疫性疾病的诊断中起着重要作用，在一定程度上也与发病机制有关。针对这些疾病，特异性 B 细胞靶向抗体在治疗中的作用日益增加。在这方面，第一个抗体靶点是 CD20，利妥昔单抗的开发和应用不仅在 B 细胞恶性肿瘤的治疗中，而且在类风湿关节炎的治疗中都发挥了重要作用。第二个候选靶点是 CD22，针对该 B 细胞标志物的第一个拮抗性抗体是依帕珠单抗，与 CD20 抗体不同，它似乎主要通过调节 B 细胞而不是通过耗竭其能力来发挥作用。依帕珠单抗最初是为治疗非霍奇金淋巴瘤而开发的，现已报道在两种原型自身免疫性疾病，即系统性红斑狼疮和原发性干燥综合征中具有良好的疗效和安全性。因此，这种新型研究用抗体可能具有独特的治疗效果，并可能与 CD20 抗体的已知作用和作用互补。
Zotero 插件